● Recruiting

A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China

Condition: Paroxysmal Nocturnal Hemoglobinuria · Sponsor: Novartis Pharmaceuticals

PhaseN/A

Planned participants80

Who can joinAll sexes, 18 Years to 80 Years

Healthy volunteersNo

About this study

The implementation of new standards for the management of PNH and the use of iptacopan in patients with PNH are expected to change the treatment landscape and improve the overall prognosis of patients. Based on these backgrounds, we plan to conduct a real-world study of iptacopan to further evaluate its impact on treatment-related outcomes, disease management, and healthcare resource utilization in Chinese patients with PNH.

This description comes directly from the study's public registry record.

Talk to the study team

Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com

Novartis Pharmaceuticals

Always discuss trial participation with your own doctor first.

Locations (14)

Novartis Investigative Site	Hefei, Anhui, China	Recruiting
Novartis Investigative Site	Guangzhou, Guangdong, China	Recruiting
Novartis Investigative Site	Guangzhou, Guangdong, China	Recruiting
Novartis Investigative Site	Shijiazhuang, Hebei, China	Recruiting
Novartis Investigative Site	Zhengzhou, Henan, China	Recruiting
Novartis Investigative Site	Zhengzhou, Henan, China	Recruiting
Novartis Investigative Site	Wuhan, Hubei, China	Recruiting
Novartis Investigative Site	Nantong, Jiangsu, China	Recruiting
Novartis Investigative Site	Nanchang, Jiangxi, China	Recruiting
Novartis Investigative Site	Changchun, Jilin, China	Recruiting
Novartis Investigative Site	Jinan, China	Recruiting
Novartis Investigative Site	Tianjin, China	Recruiting

+ 2 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06931691